The FINANCIAL — Bayer HealthCare announced the company has started to enroll patients in an international Phase III trial to evaluate its investigational compound BAY94-9027 for the treatment of hemophilia A.
As Bayer AG reported, the PROTECT VIII trial is designed to investigate whether BAY94-9027, a recombinant human factor VIII (rFVIII), can prolong the duration of protection from bleeds and with less frequent Infusions when used prophylactically, while also having the ability to treat acute bleeding events.
BAY94-9027 has been engineered to extend the circulating half-life of rFVIII while preserving full biologic activity by inserting a single cysteine (amino acid) site to its surface, which serves as an attachment site for a polyethylene glycol (PEG) polymer.
“Bayer has more than 20 years of research and clinical experience in hemophilia, and continues to invest in innovative ways to advance patient care, such as the development of BAY94-9027,” said Kemal Malik, MD, Member of the Bayer HealthCare Executive Committee and Head of Global Development. “A longer-acting rFVIII product may result in significant benefit in long-term outcomes and quality of life improvements for people with hemophilia A.”
Discussion about this post